CHEK2 and gastric cancer: The age- and sex-adjusted hazard ratio for CHEK2/1100delC heterozygotes compared with noncarriers was 5.76 (95% CI: 2.12-15.6) for gastric cancer and 3.61 (95% CI: 1.33-9.79) for kidney cancer (22).